Midkine (MDK) is a member of a new family of neurotrophic factors considered as rate-limiting growth and angiogenic factors implicated in the onset, invasion and metastatic process of neuronal tumors including neuroblastoma. We showed that all neuroblastoma cell lines highly expressed MDK indicating that it is a critical player in tumor development, which may henceforth represent an attractive therapeutic target.
Abstract
Midkine (MDK) is a member of a new family of neurotrophic factors considered as rate-limiting growth and angiogenic factors implicated in the onset, invasion and metastatic process of neuronal tumors including neuroblastoma. We showed that all neuroblastoma cell lines highly expressed MDK indicating that it is a critical player in tumor development, which may henceforth represent an attractive therapeutic target.
We showed that the knockdown of MDK expression by siRNA led to a marked and significant decrease in neuroblastoma (IGR-N91 and SH-SY5Y) cell proliferation in vitro. Using a new strategy, we then evaluated the antitumor effect of a truncated MDK protein, lacking the C-terminal 81-121 portion of the molecule (MDKΔ81-121), which may act as a dominant-negative effector for its mitogenic, angiogenic and tumorigenic activities by heterodimerizing with the wild type protein. In vitro studies showed that MDKΔ81-121 selectively inhibited MDK-dependent tumor cells and was able to strongly reduce endothelial cell proliferation and migration and to induce ER stress-mediated apoptosis.
We then investigated the effects of MDKΔ81-121 in vivo using electrotransfer of a plasmid encoding a secretable form of MDKΔ81-121 into tibialis cranialis muscles of nude mice. We showed that MDKΔ81-121 dramatically inhibited (up to 91%) tumor development and growth. This inhibition was correlated with the detection of the MDKΔ81-121 molecule in plasma and the suppression of intratumor neovascularization. Our findings demonstrate that MDK inhibition is a tractable therapeutic target for this lethal pediatric malignancy.
Introduction
Over the last decade, a number of new antiangiogenic agents have demonstrated their ability to retard tumor growth and some of them are physiological angiostatic factors that are derived upon proteolytic cleavage of native proteins. In this field, we previously evaluated antiangiogenesis and antitumor activities of a 38-kDa internal fragment of plasminogen, a 24-kDa noncollagenous domain of collagen type IV α-chains and a 20-kDa fragment of collagen XVIII, called respectively angiostatin, canstatin and endostatin (1) (2) (3) . All these fragments are known to silence cytokineinduced angiogenesis pathways by binding to integrin receptors and triggering mitochondrial apoptosis (4) (5) (6) . They specifically target endothelial cells, do not possess antineoplastic activities and should therefore be administered in combination with chemotherapy or radiotherapy to achieve a major clinical response (4, 7, 8) . Thus, the development of new anticancer strategies targeting both endothelial and neoplastic compartments should be advantageous. In this field, we already designed truncated proteins that are dominant-negative effectors of native growth factors specific to endothelial and tumor cell proliferation. They are capable of silencing the native protein by forming inactive heterodimeric molecules (9) . In particular, we demonstrated that a truncated Pleiotrophin (PTN), lacking the C-terminal 111-136 portion of the molecule (PTNΔ111-136), acted as a dominant-negative mutant that selectively inhibited in vitro the proliferation of a PTN-dependent MDA-MB-231 breast tumor and endothelial cells by silencing the VEGF-A and HIF1α pathways and breast tumor growth in vivo by 81% (10) .
In the present study, we assessed the antiangiogenesis and antitumor activities of a new dominant-negative mutant derived from the Midkine (MDK) growth factor. MDK is a 121 amino acid protein that like PTN belongs to the Heparin-Binding Growth Factor (HBGF) family and is constitutively active when it forms homodimers that are stabilized by heparin (11) . Although MDK is composed of two major N-and Cterminal domains held together by disulfide linkages, most protein activities are performed by C-terminal domain. That is the case of the lysine-rich domain of PTN 111-136 C-terminal residues, which is required for its mitogenic and tumorigenic activities (12) . MDK was identified as the ligand of different tyrosine kinase receptors such as Anaplastic Lymphoma Kinase (ALK), as well as the Receptor-like Protein Tyrosine Phosphatase (RPTPs) and the LDL-receptor-Related Protein families (LRPs) (13) (14) (15) . Through these interactions, MDK is involved in important cellular functions, promoting the growth of tumor cell lines (16) and cell survival by inhibiting apoptosis (17) and was shown to promote tumor angiogenesis (18) . In particular, MDK was shown to correlate with tumor progression and invasiveness of neuroblastoma. Indeed, plasma MDK levels were found to be significantly correlated with the status of N-myc amplification, TRKA expression and stage, which are known prognostic factors in neuroblastoma (19) . In this study, we assessed the effects of the 81-121 deleted MDK (MDKΔ81-121) lacking its last 40 amino acids, and for the first time, demonstrate that this truncated protein could act as a potent inhibitor of tumor growth and angiogenesis in a neuroblastoma tumor model.
Materials and Methods

Plasmid DNA
The pcDNA3-LacZ control plasmid encoding β-galactosidase was constructed as previously described (10) . The pcDNA3-MDKΔ81-121-MycHis plasmid was obtained by cloning the MDKΔ81-121 fragment between the BamHI and the EcoRI sites of the pcDNA3.1(+)/myc-HisA plasmid (Invitrogen). All plasmids were purified using endofree Plasmid Maxi Kit (Qiagen), and solubilized in endotoxin-free 0.9% NaCl.
Cell Culture and Conditioned Medium
Human neuroblastoma cell lines KCNR, CLB-PE, LAN-1, GIMen were a kind gift of Dr Janoueix-Lerosey (20) . The human IGR-N91 cell line was a kind gift of Dr Bénard and was established from an infiltrated bone marrow collected from a stage 4-neuroblastoma (21) . These neuroblastoma cell lines as well as SK-N-AS (ATCC CRL2137), SH-SY5Y (ATCC CRL2266), and BE(2)-M17 (ATCC CRL2267), MRC-5 cell line (ATCC CCL-171) and monkey Cos7 cells (ATCC CRL1651) were grown in DMEM supplemented with 10% fetal bovine serum. Human umbilical Smooth Muscle Cells (SMC) were a kind gift of Dr Uzan and were isolated and characterized as described previously (22) . Human Umbilical Vein Endothelial Cells (HUVEC, Lonza CC-2517) and SMC were cultured in their adequate medium from Lonza and promocell respectively (10) . Experiments involving ATCC or Lonza cell lines were mostly performed in the same year they were purchased. Authors performed no authentification on the cell lines used in this paper. To obtain Cos7-MDKΔ81-121 and Cos7-LacZ cells, Cos7 cells were transfected with 8µg of either pcDNA3-MDKΔ81-121 or pcDNA3-LacZ plasmids, using jetPEI reagent (Polyplus-Transfection). The medium was changed 4 hours after transfection and stably transfected cells were selected with Geneticin/G-418 (700µg/ml, Invitrogen). After two weeks of culture, single cells were added to a 96-well cell culture plate for subcloning and expanded in presence of G-418. Conditioned medium was harvested, aliquoted, and stored at -20°C until use.
Small interfering RNA
IGR-N91 and SH-SY5Y cells were seeded in 24-well tissue culture dishes, at a density of 5x10 4 cells per well in the appropriate medium. After 24 hours, MDK small interfering RNA (siRNA) (SI02663059, Qiagen) alone or in combination with PTN siRNA (SI00043764, Qiagen) and Scrambled siRNA (control) were added at a final concentration of 10nM. Three days after transfection cells were collected for real-time RT-PCR, or were used to perform proliferation assay. Cell supernatants were harvested and stored at -20°C for an ELISA assay.
Western Blot Analysis, ELISA and Fluorescence in situ Hybridization
Samples protein concentration was quantified using Dc Protein Assay (Biorad). PTN expression in neuroblastoma cell pellets was assessed as previously described (10) .
For MDK detection in cell pellets by Western Blot analysis, proteins were transferred to a nitrocellulose membrane (Pall) that was blocked in PBS 0.2% Tween and 5% powdered milk. Membranes were then probed with rabbit polyclonal anti-MDK antibody (1:5000; American Antigenix). Swain anti-rabbit peroxidase-linked antibody (1:1000; Dako) was used as secondary antibody. ALK Western Blot, was performed as previously described (10) . For the RPTPβ/ζ Western Blot analysis, the protein was detected using a primary rat anti-RPTPβ/ζ antibody (1:500, R&D Systems), and a secondary anti-rat antibody. Actin was detected with monoclonal anti-alpha-actin peroxidase conjugate antibody (1:50000). MDK expression in cell supernatants was quantified by an ELISA assay using a Human Midkine Construction kit (America antigenix), according to manufacturer's instructions. Fluorescence in situ hybridization was performed using the Vysis LSI ALK (2q23) dual color, break-apart rearrangement probe (Abbott Molecular).
Real-Time Reverse Transcription-PCR
The theoretical and practical aspects of real-time quantitative reverse transcription-PCR (RT-PCR) using the ABI Prism 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems) as well as the RNA extraction method, cDNA synthesis and PCR conditions, were described in detail elsewhere (10) . Target gene expression was normalized relative to an endogenous RNA control (TBP gene, which encodes the TATA box-binding protein), as previously described (10) .
Virus Construction and Infection
AdMDKΔ81-121 is a ΔE1-ΔE3 recombinant adenovirus that expresses the truncated 
Proliferation Assay
Human neuroblastoma cell lines IGR-N91, SH-SY5Y and HUVEC were seeded in 24-well tissue culture dishes at a density of 5x10 4 cells per well in complete media.
After 24 hours, the medium was replaced by 420 µl of conditioned medium Cos7 containing MDKΔ81-121, and 420µl of medium containing 1% or 5% of FBS respectively for neuroblastoma and endothelial cell lines. The culture medium was refreshed every 24 hours over 4 days, and cell survival was then quantified by a cell proliferation assay using 3-(4',5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT, 0.5mg/ml), as previously described (10) . IGR-N91, SH-SY5Y, MRC-5 cell lines, HUVEC and SMC were transduced with AdMDKΔ81-121 or AdCO1 used as control and after 4 days cell proliferation was performed as previously described (10) .
Co-culture of SMC and HUVEC
A endothelial-smooth muscle cells co-culture experiment was performed as previously described, using the 24-well transwell culture plates (0.4 µm pore size, Corning) (23 hours of incubation under normal culture conditions, the capillary-like structures were stained with Giemsa and the length of networks was quantified under phase-contrast microscopy, using Archimed and Videomat softwares (GT Vision).
Plasmid Electrotransfer
Before the electrotransfer procedure, 6-week-old female athymic mice were anesthetized with an i.p injection of 100mg/kg ketamine (Ketalar, Panpharma), and 40mg/kg xylazine (Rompun, Bayer). Forty µg of pcDNA3-MDKΔ81-121 or pcDNA3-LacZ plasmids were resuspended in 30µl sterile 0.9% normal saline and injected in both tibialis cranialis muscles of mice using a Hamilton syringe. The electrotransfer was performed with a Cliniporator system (IGEA), as previously described (10) .
Tumor Cell Inoculation
IGR-N91 cells were harvested, washed and resuspended in sterile 0.9% normal saline at a concentration of 10x10 
Statistical Analysis
Each experiment was done at least twice. Statistical significance was evaluated using the Student's t test (unilateral and unpaired). 
Results
Expression of MDK, PTN and Their Receptors
To analyze the expression of MDK and PTN in neuroblastoma cell lines (KCNR, SK-N-AS, BE(2)-M17, CLB-PE, LAN-1, SH-SY5Y, GIMen, and IGR-N91), we first quantified endogenous MDK and PTN mRNA expression by real-time RT-PCR. We showed that MDK and PTN mRNAs were detected in all of the 8 cell lines and that MDK mRNA level was significantly higher (p=0.039) than PTN mRNA (Fig. 1A) .
Indeed, in 5 cell lines (KCNR, CLB-PE, LAN-1, SH-SY5Y, and IGR-N91) MDK mRNA was 3.5 to 11-fold higher than PTN mRNA. In order to study MDK protein expression after 48 hours of culture, cell supernatants and cell extracts were analyzed using ELISA and Western Blot, respectively. Secretion of MDK in the culture media was demonstrated for all the cell lines (Fig. 1B) . The IGR-N91 cell line was found to produce and secrete the highest level of MDK and was also found to produce a high level of MDK mRNA ( Fig. 1A and 1B) . Furthermore, immunoreactive MDK protein was also detected at a high level in IGR-N91 cell extracts that also expressed a low level of PTN compared to other cell lines ( Fig. 1C and 1D ). All these results clearly showed heterogeneous expression of MDK and PTN in all the cell lines tested and that IGR-N91 and SH-SY5Y cell lines appeared to produce and secrete high levels of MDK certainly contributing to their proliferation.
To evaluate the potential contribution of HBGH signaling, we then studied the expression of its receptors (ALK, RPTPs, and LRPs) using qRT-PCR. Table 1 and SH-SY5Y (Fig. 2D) . Moreover, the level of ALK expression was not strongly correlated with the N-myc status since SH-SY5Y (not amplified for N-myc) and IGR-N91 (amplified for N-myc) respectively expressed high and low ALK levels. The second well known HBGH receptor, RPTPβ/ζ, was also detected by RT-PCR (Table   1 ) and Western Blot analysis ( (Table 1) .
In vitro Expression and Functional Characterization of MDKΔ81-121
To determine whether MDK is functionally relevant in neuroblastoma models and thus might represent a tractable therapeutic target, we examined the consequences of disrupting MDK signaling by mRNA knockdown. We transiently transfected siRNAs directed against MDK alone or in combination with PTN-targeted siRNAs into two neuroblastoma cell lines expressing high levels of MDK (IGR-N91 and SH-SY5Y) and screened growth inhibition. We first demonstrated knockdown of the mRNA and protein in these two cell lines. The MDK mRNA level was undetectable in IGR-N91 cell line, and was inhibited by 80% in SH-SY5Y cells (Fig. 3A) . MDK-specific siRNA with MDK siRNA alone (Fig. 3B) . In order to evaluate the consequence of MDK suppression on cell proliferation, we performed a proliferation assay on the cells transfected with MDK-specific siRNA alone or in combination with PTN siRNA, after 4 days of culture. Both cell lines showed significant inhibition of proliferation to MDK knockdown (Fig. 3C) . The proliferation of IGR-N91 cells was inhibited by 34% (P < 2.10 -5
) and of SH-SY5Y by 15% (P < 0.01) with MDK siRNA alone. The additive inhibitory effect of PTN siRNA on neuroblastoma cell proliferation compared to MDK siRNA alone was not significant (Fig. 3C) .
We then produced Cos7 cells expressing MDKΔ81-121 constitutively. We harvested 26 clones stably transfected with the pcDNA3-MDKΔ81-121-MycHis plasmid or pcDNA3-LacZ as control and assessed the expression of the truncated MDK protein using a specific ELISA assay on cell supernatants. The expression of MDKΔ81-121 was up to 30ng of MDKΔ81-121/mg of protein in 3 clones (clones 9, 10 and 11), whereas no expression was detected in the supernatant of Cos7 cells transfected with pcDNA3-LacZ (Fig. 3D) . As the MDKΔ81-121 is fused to the c-Myc epitope tag, we performed two different Western Blots in order to verify the molecular mass of the secreted MDKΔ81-121 protein. The first was performed towards the c-Myc epitope and showed the presence of the c-Myc tag in the 6 clones tested (Fig. 3E) . The second was performed towards the MDK epitope and showed the secreted immunoreactive protein with a molecular mass of 11.2 kDa (Fig. 3F) .
To assess the potential paracrine inhibitory effect of MDKΔ81-121 on tumor growth, we performed a cell proliferation assay using 2 neuroblastoma cell lines (IGR-N91, SHSY-5Y) expressing a high level of MDK. Conditioned media from Cos7-MDKΔ81-121 (clone 11) and Cos7-control cells were added to tumor cells in culture over 4 days. As illustrated in Fig. 4A , tumor cell proliferation was significantly inhibited by 33% for IGR-N91 cells (P < 3.10 -7 ), and by 43% for SH-SY5Y cells (P < 1.10 -6 ). To confirm these results, we used a recombinant adenovirus carrying a CMV-driven MDKΔ81-121 peptide (AdMDKΔ81-121) and an isogenic adenovirus (AdCO1) as control. The efficacy of adenovirus-mediated gene delivery was first evaluated by quantifying the proportion of cells infected with the AdCMV-GFP reporter virus after 48h by FACS analysis (Fig. 4B) . The dose of 100 multiplicity of infection (MOI) enabled us to efficiently transduce all IGR-N91 and SH-SY5Y cell lines as well as human primary endothelial cells (HUVEC). Under these conditions, transduction of IGR-N91 and SH-SY5Y cell lines by AdMDKΔ81-121 resulted in stronger significant inhibition of cell proliferation compared to the use of the Cos7-conditioned medium (Fig. 4C) .
Effect of MDKΔ81-121 on angiogenesis
To evaluate a possible antiangiogenic role of MDKΔ81-121, we first performed a proliferation assay on HUVEC, under the same conditions as for the tumor cells. We observed 60% inhibition of HUVEC proliferation (P < 5.10 (Table 2) .
As endothelial cells boarding blood vessels are surrounded by smooth muscle cells and fibroblasts, we therefore investigated the inhibitory effect of MDKΔ81-121 on SMC (Fig. 5B) and MRC-5 fibroblast (Fig. 5A ) using the MTT proliferation assay. Cell proliferation was significantly inhibited when MRC5 (P<0.0001) and SMC (P=0.005)
were infected with AdMDKΔ81-121 with 57% and 38% of inhibition respectively. In contrast when SMC were treated with MDK (100 ng/ml), no increase in cell proliferation was observed (Fig. 5C ).
We further studied the effect of AdMDKΔ81-121 on endothelial cells proliferation when co-cultured with SMC during 48 hours in the presence or not of 100 ng/ml of MDK (Fig. 5D) . In these experiments when HUVEC were treated only with MDK no 
increase in cell proliferation was observed (P=0.65). However, when HUVEC were co-cultured with SMC, MDK significantly increased the cell proliferation (P=0.0002).
Furthermore co-culture of HUVEC with AdMDKΔ81-121-transduced SMC with or without MDK repressed significantly HUVEC proliferation (Fig. 5D) .
Inhibition of Tumor Growth by MDKΔ81-121 in vivo
To confirm the antitumor potency of MDKΔ81-121 in vivo, we used a prophylactic protocol after muscle electrotransfer of the pcDNA3-MDKΔ81-121-MycHis plasmid.
We first electrotransferred 30µg pcDNA3-MDKΔ81-121-MycHis or pcDNA3-LacZ into the tibialis cranialis muscles of nude mice (n=10 per group). Seven days later, 10x10 (Fig. 6B ) and in the muscles (Fig. 6C) . IGR-N91 tumors treated with MDKΔ81-121 appeared much less vascularized than the β-galactosidase-treated control group (Fig. 6A) . Intratumoral angiogenesis was thus assessed by CD31 and alpha Smooth Muscle Actin (SMA) immunostaining of tumor sections (Fig. 6F) . The results indicated a marked reduction (37%) of intratumoral vascularization within MDKΔ81-121-treated tumors (score of 3.15 + 0.15) as compared with the β-galactosidase-treated group (score of 2.14 + 0.05) (Fig. 6D and 6E 
Discussion
PTN and MDK are members of a new family of neurotrophic factors known to be expressed in many human tumors (24) (25) (26) (27) . They participate in tumorigenesis through their action on angiogenesis and cell proliferation (18, 28) , and their expression is highly correlated with metastasis development (29) .
MDK and PTN were found to play an important role in regulating growth and differentiation in neuroblastoma, the third most common childhood solid tumor, which originates from the sympathoadrenal lineage of the neural crest. Both factors were found to be expressed in many primary neuroblastomas, but their patterns of expression were found to be quite different. PTN was found to be highly expressed in favorable neuroblastomas (stages I, II and IV-S), whereas it was expressed at a significantly lower level in advanced tumors (stages III and IV) (30) . Furthermore PTN was not expressed in aggressive neuroblastoma with N-myc amplification nor in eleven different neuroblastoma cell lines. In contrast, MDK was highly expressed in almost all primary neuroblastomas and cell lines and showed no correlation with disease stage or N-myc amplification. Unlike PTN, MDK expression was higher in undifferentiated and aggressive neuroblastomas (stage III and IV) and the plasma MDK level was thus found to be a prognostic factor for neuroblastoma patients (31).
These observations support the idea that MDK is a better molecular target candidate than PTN for neuroblastoma therapy and may therefore be considered as a new strategy for blocking tumor development and angiogenesis.
We express MDK and both receptors (36, 37) enabling the stimulation of the phosphorylation of ALK (36) and the activation of the Akt and ERK pathways (38) .
We also showed that MDKΔ81-121 inhibits endothelial cell cycling with a complete extinction of Ki67 expression, while promotes cell apoptosis via activation of a set of genes, including CHOP, implicated in ER stress-mediated apoptosis pathway. These data are consistent with the observations from U87MG glioblastoma cell line and the truncated protein PTNΔ111-136 which enhances apoptosis via CHOP protein (39) .
Angiogenesis process involves interactive dialog between endothelial and smooth muscle cells. These interactions were previously studied by Sumi et al. using an artificial blood vessel model (23) . They documented that MDK had no effect on the human aortic SMC or endothelial cells when cultured separately and these observations are in concordance with our results showing no effect of MDK on SMC and HUVEC. They also clearly showed that MDK promotes growth and glycosaminoglycan synthesis of HUVEC through its action on smooth muscle cells that are able to produce Interleukin-8. In order to evaluate if MDKΔ81-121 is able to disrupt this interaction we have co-cultured HUVEC and SMC that were transduced or not with an adenovirus expressing MDKΔ81-121. We were able to show that only the co-culture of HUVEC and SMC treated with MDK could trigger the proliferation of HUVEC. This effect was abolished by MDKΔ81-121. Tables   Table 1. Real- 
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